Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has been given an average rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $11.00.
A number of brokerages have recently issued reports on CNAT. Oppenheimer set a $14.00 target price on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 1st. ValuEngine raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. Finally, HC Wainwright reissued a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday, November 5th.
NASDAQ CNAT traded up $0.11 during trading hours on Friday, hitting $4.59. 4,812 shares of the company were exchanged, compared to its average volume of 564,178. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.39 and a quick ratio of 2.39. Conatus Pharmaceuticals has a 52-week low of $3.22 and a 52-week high of $7.95. The company has a market cap of $135.57 million, a price-to-earnings ratio of -7.64 and a beta of 1.99.
Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC boosted its holdings in shares of Conatus Pharmaceuticals by 94.6% during the 3rd quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 12,572 shares in the last quarter. Artal Group S.A. bought a new position in Conatus Pharmaceuticals in the 3rd quarter worth about $2,900,000. BlackRock Inc. boosted its stake in Conatus Pharmaceuticals by 13.4% in the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock worth $9,419,000 after purchasing an additional 191,287 shares in the last quarter. Jane Street Group LLC bought a new position in Conatus Pharmaceuticals in the 2nd quarter worth about $142,000. Finally, Paloma Partners Management Co bought a new position in Conatus Pharmaceuticals in the 2nd quarter worth about $547,000. 31.93% of the stock is owned by hedge funds and other institutional investors.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Read More: What Are Treasury Bonds?
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.